Day 3 Recap: Fall Clinical 2024
Dermatology Times
OCTOBER 26, 2024
Catch up on coverage from the third day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.
Sat.Oct 26, 2024
36 
LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets
The Dermatology Digest
OCTOBER 26, 2024
Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. “These findings indicate that upadacitinib may address an unmet medical need in patients with moderate-to-severe AD who do not achieve an adequate response while taking dupilumab,” conclude researchers who were led by Christopher Bunick, MD, PhD, an Associate Professor of Dermatology
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Innovative Insights in Skin Cancer Prognosis, Gene Expression Profiling, and Early Career Tips
Dermatology Times
OCTOBER 26, 2024
Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.
Raj Chovatiya, MD, PhD: Current Disease States and Early Career Controversies
Dermatology Times
OCTOBER 26, 2024
During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic and eczema and early career controversies.
Lebrikizumab Demonstrates Efficacy in Itch and Skin Clearance Among Patients With AD Who Discontinued Dupiluma
Dermatology Times
OCTOBER 26, 2024
The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.
Final ECZTEND Study Results Confirm Long-Term Safety and Efficacy of Tralokinumab for Moderate-to-Severe Atopic Dermatitis
Dermatology Times
OCTOBER 26, 2024
Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.
Sign up to get articles personalized to your interests!
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
More Trending
Long-Term Results Demonstrate Clinically Meaningful Improvements in Hair Regrowth Following Oral Deuruxolitinib
Dermatology Times
OCTOBER 26, 2024
Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.
Rocatinlimab Improves SCORAD in Adults With Moderate to Severe AD
Dermatology Times
OCTOBER 26, 2024
A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.
Let's personalize your content